Editor who approved publication:
Find articles by Todd M. Lee Find articles by Michael R. Putnam Find articles by Amy L. McClymont Find articles by Stephanie A. Nishimura Find articles by Michael I. Bluestone Find articles by Jeffrey A.
Received Apr 12; Accepted Jun Copyright Brusko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
This article has been cited by other articles in PMC. Human peripheral blood was collected in sodium heparin vacutainer tubes. Lentiviral transduction does not alter the capacity of Tregs to expand or suppress T responder cell proliferation. C The capacity of lentiviral transduced cells green triangles to expand in vitro is not reduced compared to mock treated Tregs black squares.
Cells were stimulated with anti-CD3 and anti-CD28 microbeads for 48 hours prior to lentiviral spinoculation. Adoptive cellular therapies using purified expanded Tregs represents an attractive alternative to systemic treatments, with results from animal studies noting increased therapeutic potency of antigen-specific Tregs over polyclonal populations.
However, current methodologies are limited in terms of the capacity to isolate and expand a sufficient quantity of endogenous antigen-specific Tregs for therapeutic intervention.
These in vitro expanded Tregs continued to express FOXP3 and functional TCRs, and maintained the capacity to suppress conventional T cell responses directed against tyrosinase, as well as bystander T cell responses.
Using this methodology in a model tumor system, murine Tregs designed to express the tyrosinase TCR effectively blocked antigen-specific effector T cell Teff activity as determined by tumor cell growth and luciferase reporter-based imaging.
Introduction Natural regulatory T cells nTregsdefined by expression of the transcription factors FOXP3  and more recently Eos play a critical role in maintaining immune tolerance .
Recent interest has been directed at this population as a means for providing cellular therapy in settings of both autoimmunity and transplantation . In comparison, relatively non-specific therapies such as anti-CD3, anti-thymocyte globulin, cytokines, and adhesion molecule based agents are associated with significant non-specific immunological effects and side-effects.
Despite these limitations, important mechanistic findings have emerged from these immune therapies. First, short term modulation of T cells can elicit long-term effects on immune tolerance .In an earlier study on complementing gene therapy with Treg adoptive transfer, Gross et al.
established that the injection of influenza hemagglutinin (HA)-specific CD4 + CD25 + Tregs, concomitant with gene transfer, enabled persistent HA transgene expression in the muscles of mice. Cytotoxic T cell responses, as well as circulating anti-IgG antibodies to HA, were impaired in HA-Treg recipients.
In this study, we examined the in vitro and in vivo gene delivery efficiency of a new, growth receptor-mediated gene transfer system in hepatocellular carcinoma (HCC). The effects of transfection of wild-type p53 using this system were also studied. Examples include hepatic gene transfer with viral vectors, genetically engineered regulatory T cells (Treg), in vivo Treg induction using immune modulatory drugs, and maternal antigen transfer.
Furthermore, an oral tolerance protocol is being developed based on transgenic lettuce plants, which suppressed inhibitor formation in hemophilic mice and dogs. Optimizing US/MB-mediates Gene Transfer to Treg The purpose of this study was to investigate the effect of ultrasound (US) and SonoVue microbubble (MB) on Treg .
New experimental therapies, such as gene and cell therapies, show promising results in pre-clinical studies in animal models of hemophilia. Examples include hepatic gene transfer with viral vectors, genetically engineered regulatory T cells (Treg), in vivo Treg induction using immune modulatory drugs, and maternal antigen transfer.
Recombinant adeno-associated viruses (AAVs) are quickly becoming the preferred viral vector for viral gene delivery for the treatment of a wide variety of genetic disorders.
However, since their use in a clinical trial targeting hemophilia B patients 10 years ago, immune responses to the AAV capsid appear to have hampered some of the early clinical gene transfer efficacy.